Dextenza in Pterygium Surgery

• Status: Recruiting
• Trial end date: 2021-07-30
• Target enrollment: 0
• Participant gender: All

Summary

DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with conjunctival autograft)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michelle Rhee MD
• Collaborator: Ocular Therapeutix, Inc.
• Treatments: Dexamethasone; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

A patient's study eye must meet the following criteria to be eligible for inclusion in the study:

• Age of at least 18 years with primary pterygia

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

• Glaucoma

• Ocular hypertension

• Prior conjunctival surgery

• Other uncontrolled ocular disease

• Ocular surgery in either eye within 3 months

• Use of eye drops other than postoperative medications and artificial tears